Infusional cyclophosphamide, doxorubicin, and etoposide (CDE) in HIV- and HTLV-I-related non-Hodgkin's lymphoma (NHL): a highly active regimen (Meeting abstract).

Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Infusional cyclophosphamide, doxorubicin, and etoposide (CDE) in HIV- and HTLV-I-related non-Hodgkin's lymphoma (NHL): a highly active regimen (Meeting abstract).

Proc Annu Meet Am Soc Clin Oncol; 12:A3 1993. Unique Identifier : AIDSLINE ICDB/93694403
Sparano JA; Wiernik PH; Strack M; Leaf A; Albert Einstein Cancer Center, Bronx, NY 10467

Abstract: 18 patients (pts) with HIV- (n=16) or HTLV-I-related (n=2) NHL received a cumulative dose of C (750 mg/m2), D (50 mg/m2), and E (240 mg/m2) given as a continuous iv infusion over 4 days, repeated every 28 or more days. All HIV+ pts had at least one poor prognostic feature associated with a median survival of 2.2-4.2 mo (Kaplan LD, JAMA 261:719, 1989). Pt characteristics: median age 39 yr (28-63); male gender, 14; HIV risk factors: iv drug abuse (12), homosexual (2), none (2); median Karnofsky performance status 70% (20-100%); median CD4, 87/mm3 (2-724); histology: large cell (3), immunoblastic (6), small noncleaved (9); extranodal disease, 5 pts (greater than or equal to 2 sites--8; marrow--5); median LDH 422 IU/L (142-7650). Complete response (CR) occurred in 14 pts (78%); partial response occurred in 3 pts (17%), of whom 1 pt is still receiving treatment. The estimated Kaplan-Meier median survival for the 14 pts who have completed therapy is 17.4 mo (for all pts and HIV+ pts as well). Toxicity was evaluable in 14 pts who have completed all therapy. Hospitalization was required after 19% of treatment cycles for neutropenic fever. Opportunistic infection occurred in 36% of pts, bacteremia in 21%, and candidemia in 7%; there was one treatment-related death due to disseminated aspergillosis. Infusional CDE is a highly active, tolerable regimen in pts with HIV-related NHL and merits further study. Our encouraging results are not likely to be due to selection of favorable pts, since all pts had at least one poor prognostic feature.

Keywords: Adult Antineoplastic Agents, Combined/ADVERSE EFFECTS/*THERAPEUTIC USE Cyclophosphamide/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS Dose-Response Relationship, Drug Doxorubicin/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS Drug Administration Schedule Etoposide/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS Female Follow-Up Studies Human Infusions, Intravenous Leukemia-Lymphoma, T-Cell, Acute, HTLV-I-Associated/*DRUG THERAPY/ MORTALITY/PATHOLOGY Lymph Nodes/PATHOLOGY Lymphoma, AIDS-Related/*DRUG THERAPY/MORTALITY/PATHOLOGY Lymphoma, Non-Hodgkin's/*DRUG THERAPY/MORTALITY/PATHOLOGY Male Middle Age Survival Rate ABSTRACT
931230
M93C0824

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .